Hepatitis C
in [Hepatitis]
|
Chronic Marijuana Use May Increase Fibrosis for Hep C Patients January 14, 2008 Hepatitis C, Liver Fibrosis and Marijuana According to a recently published California study, people with Hepatitis C who use cannabis daily risk developing fibrosis nearly seven times more than non-users. Chronic Marijuana Use May Increase Fibrosis for Hep C Patients Sunday, January 06 2008 ... 21 Jan 2008 17:24
Latest from Clinical Care Options (9/9) Conclusions Conclusions Nezam H. Afdhal, MD, FRCPI: In summary, a number of novel HCV therapies were discussed at the 2007 Annual Meeting of the AASLD. Some of the major issues discussed concerning these novel approaches include resistance, the role of ribavirin in future regimens, the efficacy of polymerase in... 21 Jan 2008 12:52
Latest from Clinical Care Options (8) Anti-HCV Activity With GI-5005 Anti-HCV Activity With GI-5005, a Yeast-Based Immunotherapy Ira M. Jacobson, MD: GI-5005 is a novel immunotherapeutic agent in which heat-activated Saccharomyces cerevisiae yeast expresses the HCV NS3 protease and core proteins. Since yeast is immunogenic, exposure to yeast that expresses viral prot... 21 Jan 2008 11:11
Latest from Clinical Care Options (7) controlled release Recombinant Interferon Alfa-2b Phase IIa Trial of Controlled-Release Recombinant Interferon Alfa-2b Nezam H. Afdhal, MD, FRCPI: The next interesting study was the phase IIa trial of controlled-release recombinant (CRR) interferon alfa-2b, another novel long-acting interferon. This compound is composed of interferon alfa-2b in a b... 21 Jan 2008 11:11
Latest from Clinical Care Options (6) Albinterferon alfa-2b Albinterferon Alfa-2b in Treatment-Naive or -Experienced Patients David R. Nelson, MD: Two data sets were presented at this meeting using albinterferon alfa-2b, which is a long-acting molecule created by the genetic fusion of human serum albumin with interferon alfa-2b. Since the half-life of this r... 21 Jan 2008 11:11
Latest from Clinical Care Options (5) Nitazoxanide Anti-HCV Activity Observed With Nitazoxanide Nezam H. Afdhal, MD, FRCPI: Nitazoxanide is a thiazolide anti-infective with activity against a number of viruses including both HCV and hepatitis B virus and is approved for use as an antiprotozoal agent for gastrointestinal infections. An in vitro study... 21 Jan 2008 11:11
Latest from Clinical Care Options (4) VCH 759 and GS 9190 Clinical Studies With NS5B Polymerase Inhibitors VCH-759 and GS-9190 Nezam H. Afdhal, MD, FRCPI: Two studies involving the nonnucleoside inhibitors of HCV NS5B polymerase, VCH-759 and GS-9190, were presented at the meeting.[21,22] Both compounds had previously exhibited similar reductions in HCV RNA d... 21 Jan 2008 11:11
Latest from Clinical Care Options (3) R7128 Treatment With R7128 in Previous Nonresponders Ira M. Jacobson, MD: R7128, another nucleoside analogue polymerase inhibitor, demonstrated very respectable levels of viral suppression, maximal at the highest dose of 1500 mg twice daily, in a study by Reddy and colleagues (Capsule Summary).[20] In thi... 21 Jan 2008 11:11
Latest from Clinical Care Options (2) R1626 Efficacy, Safety, and Resistance Analysis With R1626 David R. Nelson, MD: Two studies involving the nucleoside polymerase inhibitor R1626 were presented during the meeting.[13,14] Pockros and colleagues[13] presented an interim analysis of a phase IIa clinical trial evaluating 4 weeks of R162... 21 Jan 2008 11:11
Latest from Clinical Care Options: Telaprevir Clinical Studies of the Investigational Protease Inhibitor Telaprevir Nezam H. Afdhal, MD, FRCPI: A series of interesting studies on the novel hepatitis C virus (HCV) NS3/4A protease inhibitor telaprevir (formerly VX-950) were presented at the 2007 Annual Meeting of the American Association for the St... 21 Jan 2008 11:11 |